Reuters is reporting that:
"The retirement of Dr. Janet Woodcock as head of the Food and Drug Administration’s pharmaceutical division is at least a year away, but already the industry she regulates is worrying about who will replace her. Over the past 20 years Woodcock, who is 65, has reshaped the drug approval process, relaxing the criteria needed for certain drugs to reach the market - especially those that represent scientific breakthroughs. Last year, the agency approved 39 new drugs, the most since 1996.
“That is good news for drug companies who depend on product approvals to fuel profit growth, and some fear that once Woodcock leaves the pace of drug approvals will slow. ‘No one is seeing that luminous, next-generation leadership,’ said Dr. Robert Meyer, a former top medical reviewer at the FDA who subsequently joined drug maker Merck & Co as a vice president and in March.”
You may recall that is was Woodcock who nixed Merck’s petition to study the effects of finasteride in teenage boys:
propeciasideeffects.co.uk/me … -pill.html
The full Reuters story here: